Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2226 : JHOC-9  update : 2018/08/02
CommentHuman cell line derived from ovary cancer. Clear cell carcinoma. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.Cell Bank
Fax. +81-29-836-9130
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 2005
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 34 years
Tissue ovary
Case history clear cell carcinoma
Metastastatic ability Yes
Metastatsd tissue lymph node
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM/HamF12 + 20% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% trypsin + 0.02% EDTA) or (0.25% trypsin + 0.02% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 0
User's Publication 10


To topTop
Reference

To topTop
User's Publication
11839  Kuroda T, Ogiwara H, Sasaki M, Takahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T.  Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.  Gynecol. Oncol.  2019    PubMed ID: 31604667
9662  Jennifer X. Ji et al  Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type  bioRxiv  2019  November 17 
9659  Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich  Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models  Mol Cancer Ther   2017  16(5):850-860  PubMed ID: 28292935
7404  Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.  Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.  Mol. Carcinog.  2016  55:832-41  PubMed ID: 25856562
9636  Nozomu Yanaihara, Yukiko Noguchi 1, Misato Saito 1, Masataka Takenaka 1, Satoshi Takakura 2, Kyosuke Yamada 1, Aikou Okamoto 1  MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma  PLoS One  2016  11(9):e0162584  PubMed ID: 27612152
9661  Chinami Makii, Katsutoshi Oda, Yuji Ikeda, Kenbun Sone, Kosei Hasegawa, Yuriko Uehara, Akira Nishijima, Kayo Asada, Takahiro Koso, Tomohiko Fukuda, Kanako Inaba, Shinya Oki, Hidenori Machino, Machiko Kojima, Tomoko Kashiyama, Mayuyo Mori-Uchino, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Tetsu Yano, Keiichi Fujiwara, Hiroyuki Aburatani, Yutaka Osuga, Tomoyuki Fujii  MDM2 Is a Potential Therapeutic Target and Prognostic Factor for Ovarian Clear Cell Carcinomas With Wild Type TP53  Oncotarget  2016  7(46):75328-75338  PubMed ID: 27659536
7410  Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.  Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.  Int. J. Oncol.  2015  46:2389-98  PubMed ID: 25846456
9658  Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii  Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423  PLoS One  2014  9(2):e87220  PubMed ID: 24504419
9635  Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni  Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates With Worsened Prognosis  PLoS One  2013  8(3):e57724  PubMed ID: 23469222
9657  Nozomu Yanaihara, Michael S Anglesio, Kazunori Ochiai, Yukihiro Hirata, Misato Saito, Chie Nagata, Yasushi Iida, Satoshi Takakura, Kyosuke Yamada, Tadao Tanaka, Aikou Okamoto  Cytokine Gene Expression Signature in Ovarian Clear Cell Carcinoma  Int J Oncol   2012  41(3):1094-100  PubMed ID: 22751940



Back Back Return Top Page